Late breaking research from Bhardwaj Lab, Matt Galsky and colleagues at #AACR2024 : Atezolizumab plus neoantigen vaccination for #bladdercancer
abstractsonline.com/pp8/#!/20272/p…
Poster, April 8, 9-12:30
Icahn School of Medicine at Mount Sinai

“FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors”

Big news for #BladderCancer and all advanced cancers FDA Oncology Matt Galsky Andrea Apolo, M.D. Dr. Bishoy M. Faltas Perlmutter Cancer Center at NYU Langone Health

Congrats to Dr. Bishoy M. Faltas on another major achievement.
eipm.weill.cornell.edu/news/dr-bishoy…
Bladder Cancer Advocacy Network UroToday.com Uromigos

Excited to share our new paper just published Nature Communications WCM GU Cancer Weill Cornell Medicine nature.com/articles/s4146… Great collaboration between my lab with Olivier Elemento WCM Englander Institute for Precision Medicine and J.M. Mosquera Weill Cornell Medicine Pathology 🔬 Full tweetorial below with more updates to come. Stay tuned!

Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a U.S. FDA pooled analysis - via JNCI. 1st author Jaleh Fallah, last author Laleh Amiri-Kordestani, MD.
academic.oup.com/jnci/advance-a…

#OCEPublications

There continues to be a significant disconnect between the research concept of “ #NEPC ” vs the clinical experience

For a perspective from the clinic, consider this quick read Journal of Clinical Investigation

Deciphering the Enigma of #Neuroendocrine #ProstateCancer
jci.org/articles/view/…

Grateful to NewYork-Presbyterian for profiling our research #FaltasLab & our vision to improve #BladderCancer patient outcomes by building a world-class research program Weill Cornell Medicine. Read more here: nyp.org/advances/artic…

🎉Congratulations Dr. Fatima Karzai!🎉
Fatima Yaftali Karzai, M.D. NCI CCR GU Malignancies NCI Center for Cancer Research

CAR in autoimmune disease is a new frontier

Summary of clinical trials in advanced non-clear cell RCC #GU24 . The studies are small & pathology mixed ‘the moons of Jupiter’. The focus on PD1 & VEGF was not driven by the biology. Large randomised trials such as SAMETA exploring MET in selected papillary seems like progress.

'Our goal is not to practice today's medicine, but to create the medicine of tomorrow.' - Dr. Steven A. Rosenberg

The National Comprehensive Cancer Network (NCCN) Bladder Cancer Guidelines v1.2024 are now available. It has been a very active time in bladder cancer therapeutic development. Important updates on the treatment of locally advanced/metastatic disease and in many other areas. #BladderCancer
nccn.org/home

⚡️ Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2

#bladderCancer Petros Grivas Ashish M. Kamat, MD, MBBS Roger Li Andrea Necchi Philippe spiess

sciencedirect.com/science/articl…

Excited to announce the 9th edition of the International Immunoschool. This year's theme is 'Challenges and Opportunities in Cancer Immunotherapy' with talks from Eric Vivier Jonathan Kagan Kate Chiappinelli Vinod BalachandranMD Kamphorst Lab & more. Register FREE >>> loom.ly/9no6dhU

Did you ever wonder why cisplatin and carboplatin perform differently in urothelial cancer? So did we.
Enrique Grande Peter Black Sanjeev Mariathasan Ian Davis The Tisch Cancer Institute Uromigos UroToday.com Cell Reports Medicine Bladder Cancer Advocacy Network Society for Immunotherapy of Cancer Cancer Research Institute

National Comprehensive Cancer Network (NCCN) #bladdercancer Guidelines 2024 now include pembrolizumab as a therapeutic option for pts with BCG-unresponsive Ta/T1 papillary tumors without Tis. Based on the results of Keynote-057 Cohort-B trial Chiara Mercinelli Valentina Tateo Antonio Cigliola UroToday.com Ashish M. Kamat, MD, MBBS Petros Grivas

WATCH: What is the impact of #mentorship ? NCI Director Dr. Kimryn Rathmell shares the transformative role mentorship has played in shaping her career and life choices in recognition of #NationalMentoringMonth Month.

It’s time to register for Rare Disease Day at NIH! Join us at the NIH main campus or via a virtual livestream on Thursday, Feb. 29. This event will feature discussions, stories, posters, and more. Everyone is welcome. go.nih.gov/z3f6BVV #RDDNIH

After spending my early career working on AMBASSADOR at the NCI Center for Cancer Research NIH learning from Andrea Apolo, M.D. it’s a surreal feeling finally to see the data. While the OS wasn’t met I have to wonder how the FDAapproval of adjNivo impacted the data with pts in obvs going onto PD1.

Here we go Andrea Apolo, M.D. #gu24